Study of a New Antibody for Breast Cancer Treatment
Author Information
Author(s): Tokuda Y, Watanabe T, Omuro Y, Ando M, Katsumata N, Okumura A, Ohta M, Fujii H, Sasaki Y, Niwa T
Primary Institution: Tokai University School of Medicine
Hypothesis
Can a humanized anti-HER2 monoclonal antibody effectively treat patients with HER2/neu-overexpressing metastatic breast cancer?
Conclusion
The study found that the antibody MKC-454 is well tolerated and shows effectiveness in treating patients with refractory metastatic breast cancer.
Supporting Evidence
- The mean trough serum concentrations increased with higher doses of MKC-454.
- Two patients showed objective tumor responses, with one achieving a complete response.
Takeaway
Researchers tested a new medicine on 18 patients with a tough kind of breast cancer, and it worked well for some of them.
Methodology
A phase I pharmacokinetic dose escalation study was conducted with 18 patients receiving varying doses of MKC-454.
Limitations
The study had a small sample size and was limited to patients refractory to chemotherapy.
Participant Demographics
Patients with metastatic breast cancer who overexpress the HER2 proto-oncogene.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website